News - Generics, Licensing

Filter

Current filters:

GenericsLicensing

Popular Filters

1 to 25 of 52 results

Medicines Patent Pool broadens collaboration with Gilead Sciences

24-07-2014

The Medicines Patent Pool (MPP) has entered into a new licensing agreement with US biotech firm Gilead…

Anti-viralsChinaGenericsGilead SciencesIndiaLicensingProductiontenofovir alafenamide

Prasco to market authorized generic of NeoProfen Injection

22-05-2014

Privately held US generic drugmaker Prasco Laboratories has entered into a distribution and supply agreement…

GenericsLicensingNeoProfenNeurologicalPrasco LaboratoriesRecordatiUSA

Grunenthal strengthens pain product portfolio with European rights to etoricoxib

07-05-2014

Family-owned German drugmaker Grunenthal Group today announced the signing of an exclusive promotion…

etoricoxibEuropeGenericsGrunenthalLicensingMerck & CoNeurological

Prosonix and Mylan in deal for Flixotide and Flovent generics

15-04-2014

Prosonix, a UK-based company which is developing a portfolio of inhaled “Respiratory Medicines by Design,”…

FloventGenericsGlaxoSmithKlineGlobalLicensingMylan LaboratoriesProsonixRespiratory and Pulmonary

Sandoz to commercialize Taiwan Liposome’s antifungal

Sandoz to commercialize Taiwan Liposome’s antifungal

19-12-2013

Taipei-based biopharmaceutical company Taiwan Liposome Company has entered into a collaboration agreement…

Amphotericin BAntibiotics and Infectious diseasesAsia-PacificGenericsLicensingNovartisSandozTaiwan Liposome

Sandoz in deal to market authorized generic of Shire’s Adderall XR in USA

Sandoz in deal to market authorized generic of Shire’s Adderall XR in USA

03-12-2013

UK drugmaker Shire says that its subsidiary Shire US Inc has entered into an agreement to supply an authorized…

Adderall XRGenericsLicensingNeurologicalNorth AmericaNovartisSandozShire

Hikma in $40 million deal to enhance delivery of generic injectables

20-11-2013

USA-based Unilife Corp has signed a long-term commercial supply contract with Jordan-headquartered Hikma…

GenericsHikma PharmaceuticalsLicensingMarkets & MarketingUnilife Corp

Acura Pharma settles with Par and Impax over Oxecta

Acura Pharma settles with Par and Impax over Oxecta

11-10-2013

US specialty pharma firm Acura Pharmaceuticals saw its shares leap as much as 28% after it said that…

Acura PharmaceuticalsGenericsImpax LaboratoriesLicensingNeurologicalNorth AmericaOxectaPar PharmaceuticalPatents

Epic Pharma gets rights to sell 12 generics

08-10-2013

Elite Pharmaceuticals (OTCBB: ELTP) has signed a manufacturing and license agreement with fellow USA-based,…

Epic PharmaGenericsLicensingNorth AmericaProduction

Baxter and Coherus in up to $246 million deal for biosimilar etanercept

04-09-2013

US companies Baxter International (NYSE:BAX) and Coherus Biosciences have entered into an exclusive collaboration…

AmgenAnti-Arthritics/RheumaticsBaxter InternationalBiotechnologyCoherus BioSciencesEnbreletanerceptGenericsLicensingResearch

Biocad enters deal for exporting rituximab biosimilar to Turkey

22-08-2013

Biocad, one of Russia's leading biotechnology companies, has signed a definitive agreement on the export…

BiocadBiotechnologyEuropeGenericsKocak FarmaLicensingMabTheraMarkets & MarketingOncologyRituxanrituximabRoche

Avanir agrees settlement with Sandoz over Nuedexta

14-08-2013

US drugmaker Avanir Pharmaceuticals (Nasdaq: AVNR) has entered into a settlement agreement with Swiss…

Avanir PharmaceuticalsGenericsLicensingNeurologicalNorth AmericaNuedextaPharmaceuticalSandoz

Mylan strikes deal for Parkinson's disease drug Stalevo

26-07-2013

US generics firm Mylan (Nasdaq: MYL) and Finland-based drugmaker Orion Corp (Nasdaq OMX Helsinki: ORNAV)…

GenericsLicensingMylan LaboratoriesNeurologicalNorth AmericaOrion CorpPharmaceuticalStalevo

US FTC will continue to challenge "anticompetitive" pharma pay-for-delay deals

24-07-2013

The Federal Trade Commission told a Senate Judiciary subcommittee yesterday (July 23) that it will continue…

GenericsLegalLicensingMarkets & MarketingNorth AmericaPharmaceutical

Forest agrees another license deal for Bystolic

22-07-2013

US drugmaker Forest Laboratories (NYSE:FRX) and Forest Laboratories Holdings have reached a settlement…

Amerigen PharmaceuticalsBystolicCardio-vascularForest LaboratoriesGenericsLicensingNorth AmericaPharmaceutical

Lupin to market MSD vaccine in India

19-07-2013

US pharma giant Merck & Co (NYSE: MRK), known as MSD outside of North America, has entered into an India…

Asia-PacificGenericsLicensingPharmaceuticalVaccines

Actavis and Valeant to co-promote Zovirax and Cordran Tape

07-04-2013

Valeant Pharmaceuticals International (TSX: VRX) entered into an agreement, effective immediately, for…

ActavisAnti-viralsCordran TapeGenericsLicensingMarkets & MarketingMylan LaboratoriesNorth AmericaValeant PharmaceuticalsZovirax Ointment

Ranbaxy in deal with Alembic to market bioequivalent Pristiq in USA

05-03-2013

The US subsidiary of India's largest drugmaker, Ranbaxy Laboratories (AB: BO), which is majority owned…

Alembic PharmaceuticalsDaiichi SankyoGenericsLicensingMarkets & MarketingNeurologicalNorth AmericaPatentsPfizerPristiqRanbaxy Laboratories

Briefs: Ablynx inks research deal with Spirogen; Solent Pharma debuts

25-02-2013

Belgium drug developer Ablynx (Euronext Brussels: ABLX]) has entered into a research collaboration with…

AblynxGenericsidebenoneIdecortexLicensingMarkets & MarketingNeurologicalOncologyPharmaceuticalResearchSolent PharmaSpirogen

Mylan extends deal with Bioton to biosimilar insulins, as Actavis pulls out of JV

14-02-2013

US generic drugmaker Mylan (Nasdaq: MYL) said yesterday that it has entered into a definitive agreement…

ActavisBiotechnologyBiotonDiabetesEli LillyGenericsHumalogLantusLicensingMarkets & MarketingMylan LaboratoriesNovo NordiskNovoLogSanofi

Japan Pharma: Expectations for 2013, by P Reed Maurer

03-01-2013

The biggest non-event in the Japan health care market during 2013 will be no reimbursement price reductions,…

Asia-PacificGenericsLicensingMergers & AcquisitionsPharmaceuticalPricingResearch

Teva fleshes out restructuring plan; licenses Xenon pain drug for $376 million

12-12-2012

Teva Pharmaceutical Industries (NYSE: TEVA's new chief executive Jeremy Levin has outlined the company's…

CopaxoneFinancialGenericsLicensingPatentsPharmaceuticalResearchTeva Pharmaceutical IndustriesXenon Pharmaceuticals

1 to 25 of 52 results

Back to top